Anti-CD 30 Antibody Treatment In Vitro Apoptosis in Human Eosinophils by Extremely Rapid and Intense Induction of Fukuda

[1]  M. Croft.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? , 2003, Nature Reviews Immunology.

[2]  A. Al-Shamkhani,et al.  Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30 , 2002, European journal of immunology.

[3]  M. Fujimoto,et al.  Elevated circulating soluble CD30 levels in patients with polymyositis/dermatomyositis , 2001, The British journal of dermatology.

[4]  V. Pistoia,et al.  Plasma levels of soluble CD30 are increased in children with chronic renal failure and with primary growth deficiency and decrease during treatment with recombination human growth hormone. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  C. Duckett,et al.  Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. , 2000, Blood.

[6]  A. Winoto,et al.  The TNF Receptor Family Member CD30 Is Not Essential for Negative Selection1 , 2000, The Journal of Immunology.

[7]  H. Kanegane,et al.  CD30 expression on circulating memory CD4+ T cells as a Th2‐dominated situation in patients with atopic dermatitis , 2000, Allergy.

[8]  M. Ferrarini,et al.  Engagement of CD30 shapes the secretion of cytokines by human γ δ T cells , 2000 .

[9]  M. Caproni,et al.  Soluble CD30 and Cyclosporine in Severe Atopic Dermatitis , 2000, International Archives of Allergy and Immunology.

[10]  R. Rodríguez-Roisín,et al.  Evaluation of CD30 as a marker for th2 lymphocytes in bronchoalveolar lavage in interstitial lung diseases. , 2000, Respiratory medicine.

[11]  V. Diehl,et al.  Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. , 2000, Blood.

[12]  T. Ellis,et al.  Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. , 2000, Hybridoma.

[13]  G. Inghirami,et al.  CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. , 1999, Journal of immunology.

[14]  Peter Scheurich,et al.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF , 1999, The EMBO journal.

[15]  A. Wardlaw,et al.  Expression of Bcl-2 and its homologues in human eosinophils. Modulation by interleukin-5. , 1999, American journal of respiratory cell and molecular biology.

[16]  C. Kurts,et al.  Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells , 1999, Nature.

[17]  Davis,et al.  Soluble cytokine receptor CD30 in atopic disorders: a case‐control study , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  Berger,et al.  Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease , 1999, Clinical and experimental immunology.

[19]  B. Wedi,et al.  IL-4-induced apoptosis in peripheral blood eosinophils. , 1998, The Journal of allergy and clinical immunology.

[20]  Toshiki Watanabe,et al.  CD30: expression and function in health and disease. , 1998, Seminars in immunology.

[21]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[22]  F. Levi-Schaffer,et al.  Mast cells enhance eosinophil survival in vitro: role of TNF-alpha and granulocyte-macrophage colony-stimulating factor. , 1998, Journal of immunology.

[23]  H. Mizoguchi,et al.  Dual action of CD30 antigen: anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells. , 1998, International journal of hematology.

[24]  Mccluggage,et al.  Anaplastic large cell malignant lymphoma with extensive eosinophilic or neutrophilic infiltration , 1998, Histopathology.

[25]  S R Sprang,et al.  Modularity in the TNF-receptor family. , 1998, Trends in biochemical sciences.

[26]  W. Telford,et al.  CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. , 1997, Cellular immunology.

[27]  C. Thompson,et al.  CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. , 1997, Genes & development.

[28]  K. Kliche,et al.  CD30 ligand in lymphoma patients with CD30+ tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Puddu,et al.  T-helper 2 involvement in the pathogenesis of bullous pemphigoid: role of soluble CD30 (sCD30) , 1997, Archives of Dermatological Research.

[30]  A. Scheynius,et al.  Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD) , 1997, Clinical and experimental immunology.

[31]  M. de Carli,et al.  An update on human Th1 and Th2 cells. , 1997, International archives of allergy and immunology.

[32]  Kenji Matsumoto,et al.  Regulation of α4 integrin–mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1 , 1997 .

[33]  C. Thompson,et al.  Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2 , 1997, Molecular and cellular biology.

[34]  Ko Okumura,et al.  Tumor Necrosis Factor Receptor-associated Factor (TRAF) 5 and TRAF2 Are Involved in CD30-mediated NFκB Activation* , 1997, The Journal of Biological Chemistry.

[35]  F. Herrmann,et al.  Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. , 1996, Blood.

[36]  D. Wong,et al.  Role of the eosinophil in allergic reactions. , 1996, The European respiratory journal. Supplement.

[37]  F. Symon,et al.  Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. , 1996, Blood.

[38]  H. Griesser,et al.  Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice , 1996, Cell.

[39]  Soo-Young Lee,et al.  T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors , 1996, The Journal of experimental medicine.

[40]  C. Bertrand,et al.  Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. , 1995, The Journal of clinical investigation.

[41]  B. Falini,et al.  High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints , 1995, Clinical and experimental immunology.

[42]  K. Matsumoto,et al.  Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. , 1995, Blood.

[43]  R. Egan,et al.  Effects of an antibody to interleukin-5 in a monkey model of asthma. , 1995, American journal of respiratory and critical care medicine.

[44]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[45]  M. Tiemann,et al.  Shedding of the soluble form of CD30 from the Hodgkin‐analogous cell line L540 is strongly inhibited by a new CD30‐specific antibody (Ki‐4) , 1995, International Journal of Cancer.

[46]  H. Kita,et al.  Tyrosine phosphorylation and inositol phosphate production: are early events in human eosinophil activation stimulated by immobilized secretory IgA and IgG? , 1994, The Journal of allergy and clinical immunology.

[47]  M. Pfreundschuh,et al.  Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. , 1994, Molecular immunology.

[48]  R. Schleimer,et al.  The effects of glucocorticoids on human eosinophils. , 1994, The Journal of allergy and clinical immunology.

[49]  D. Green,et al.  Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Stein,et al.  High serum level of the soluble form of CD30 molecule in the early phase of HIV‐1 infection as an independent predictor of progression to AIDS , 1994, AIDS.

[51]  S. Stafford,et al.  Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis , 1994, The Journal of experimental medicine.

[52]  S. Pileri,et al.  Cultured human NK cells express the Ki‐l/CD30 antigen , 1993, British journal of haematology.

[53]  A. Carbone,et al.  High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large‐cell ki‐1‐positive lymphomas in HIV‐1‐positive patients , 1993, International journal of cancer.

[54]  A. Osterhaus,et al.  Modulation of cell surface molecules during HIV‐1 infection of H9 cells. An immunoelectron microscopic study , 1992, AIDS.

[55]  C. Sanderson.  Interleukin-5, Eosinophils, and Disease , 1992 .

[56]  C. Haslett,et al.  Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. , 1992, Journal of immunology.

[57]  L. Gerschenson,et al.  Apoptosis: a different type of cell death , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  H. Stein,et al.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.

[59]  K. Blaser,et al.  An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. , 1991, Journal of immunological methods.

[60]  W. Owen,et al.  Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. , 1991, The Journal of clinical investigation.

[61]  H. Kita,et al.  Glucocorticoids inhibit cytokine-mediated eosinophil survival. , 1991, Journal of immunology.

[62]  P. Tai,et al.  Effects of IL‐5, granulocyte/macrophage colony‐stimulating factor (GM‐CSF) and IL‐3 on the survival of human blood eosinophils in vitro , 1991, Clinical and experimental immunology.

[63]  R. Schleimer,et al.  Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. , 1991, Journal of immunology.

[64]  G. Gleich.  The eosinophil and bronchial asthma: current understanding. , 1990, The Journal of allergy and clinical immunology.

[65]  W. Owen,et al.  Hemopoietins for eosinophils. Glycoprotein hormones that regulate the development of inflammation in eosinophilia-associated disease. , 1989, Hematology/oncology clinics of North America.

[66]  R. Schleimer,et al.  Human endothelial cells prolong eosinophil survival. Regulation by cytokines and glucocorticoids. , 1989, Journal of immunology.

[67]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[68]  J. Gamble,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. , 1986, The Journal of clinical investigation.

[69]  鈴木 雅登.  Actin assembly is a crucial factor for superoxide anion generation from adherent human eosinophils , 2005 .

[70]  B Vyas,et al.  Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. , 2000, Blood.

[71]  A. van den Berg,et al.  Immune escape mechanisms in Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  J. Inoue,et al.  A novel domain in the CD 30 cytoplasmic tail mediates NF κ B activation , 1998 .

[73]  A. Carbone,et al.  The role of eosinophils in the pathobiology of Hodgkin's disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  A. Wardlaw,et al.  Eosinophils: biology and role in disease. , 1995, Advances in immunology.

[75]  M. Ebisawa,et al.  Platelet-activating factor-induced activation and cytoskeletal change in cultured eosinophils. , 1990, International archives of allergy and applied immunology.

[76]  M. Samoszuk,et al.  Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. , 1990, Blood.

[77]  E. Whitcomb,et al.  Modulation of human peripheral blood eosinophil function by tumor necrosis factor-alpha. , 1989, International archives of allergy and applied immunology.